ChemoCentryx Inc. (NASDAQ:CCXI)’s share price was up 5.1% on Monday . The stock traded as high as $4.77 and last traded at $4.77, with a volume of 57,097 shares. The stock had previously closed at $4.54.

Several equities analysts recently weighed in on CCXI shares. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Wednesday, April 27th. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th.

The company’s 50-day moving average is $4.86 and its 200-day moving average is $3.79. The stock’s market capitalization is $202.85 million.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Equities analysts expect that ChemoCentryx Inc. will post ($0.35) earnings per share for the current year.

In related news, Director Geoffrey M. Parker acquired 40,000 shares of the firm’s stock in a transaction dated Friday, May 13th. The stock was bought at an average price of $4.03 per share, for a total transaction of $161,200.00. Following the acquisition, the director now directly owns 13,514 shares of the company’s stock, valued at $54,461.42. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas A. Edwards purchased 25,000 shares of ChemoCentryx stock in a transaction that occurred on Monday, May 16th. The shares were acquired at an average price of $4.05 per share, with a total value of $101,250.00. Following the acquisition, the director now directly owns 41,977 shares of the company’s stock, valued at approximately $170,006.85. The disclosure for this purchase can be found here.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.